Latest News

Bayer advances cell and gene therapies for Parkinson’s disease June 10, 2021

Bayer has announced that two subsidiaries are progressing investigational cell and gene therapies as potential treatments for Parkinson’s disease.

Queensland enters the push to grow Australian manufacturing June 10, 2021

The push to enhance Australia's sovereign capability to manufacture vaccines and medicines just got more confused with the Queensland government announcing $20 million for a new facility at the Woolloongabba medical precinct in Brisbane.

World Bank says no to IP waiver as WTO debate resumes June 10, 2021

The World Bank has announced it opposes the proposed waiver of intellectual property rights for COVID-19 vaccines as negotiations resume at the World Trade Organization.

Engage on upcoming UDI system changes June 10, 2021

Medtech stakeholders can be kept abreast of how the establishment of a new Australian Unique Device Identification system will affect their companies through the Therapeutic Goods Administration’s upcoming webcast series.

Proteomics International announces new executive appointments June 10, 2021

Proteomics International Laboratories (ASX:PIQ) has announced the expansion of its executive team with the appointments of Vik Malik as its new chief commercialisation officer (CCO) and Jacqueline Gray as its new chief financial officer.

Immutep reports final data from phase one study of LAG-3 Therapy June 8, 2021

Immutep (ASX:IMM), a company developing novel LAG-3 related immunotherapy treatments for cancer and autoimmune disease, has announced what it describes as "encouraging final data" from its phase one INSIGHT-004 study.

First stroke patient treated with Clinuvel's afamelanotide June 8, 2021

Clinuvel's has announced that its drug afamelanotide has been administered to a first patient diagnosed with an acute arterial ischaemic stroke (AIS) enrolled in a clinical trial (CUV801).

Telix and ATS awarded 'Eurostars’ grant for alpha therapy June 8, 2021

Advanced Nuclear Medicine Ingredients, a wholly-owned European subsidiary of Telix, and Alpha Therapy Solutions have been jointly awarded a €990,000 ($1.56 million) ‘Eurostars-2’ research grant from the EUREKA Association.

PYC Therapeutics advances program for inherited eye disease therapy June 8, 2021

PYC Therapeutics (ASX:PYC), a company developing RNA therapeutics for inherited diseases, has announced it intends to accelerate a key program towards clinical trials.

Taking action against IP protection threats June 8, 2021

AusBiotech is inviting its Members to join it in signing a global, open letter in opposition to the ongoing risk to international IP protection that is before the World Trade Organization.

First patient dosed in combination trial of QBiotics and MSD therapies June 3, 2021

QBiotics Group has dosed the first patient in the Phase Ib/IIa clinical trial of its lead oncology molecule, tigilanol tiglate, in combination with MSD’s immune checkpoint inhibitor KEYTRUDA (pembrolizumab).

2022 sees biggest week in biotech heading to WA June 3, 2021

Two of Australia’s premier life science industry events are heading to Western Australia in 2022, for the first time in more than 15 years.

Most Read

New Stories

Bayer advances cell and gene therapies for Parkinson’s disease

Queensland enters the push to grow Australian manufacturing

World Bank says no to IP waiver as WTO debate resumes

Engage on upcoming UDI system changes

Proteomics International announces new executive appointments

Immutep reports final data from phase one study of LAG-3 Therapy

First stroke patient treated with Clinuvel's afamelanotide

Sign In